TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03970109
Drug: ANS-6637
Normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a day
Study: NCT01313572
Drug: Apadenoson SPECT-MPI
Normalized name: spelt seed extract
DrugBank: Apadenoson (DB05009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apadenoson single bolus IV injection 100 or 150 ug
Study: NCT03221257
Drug: Pirfenidone (PFD)
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
Study: NCT03221257
Drug: Mycophenolate Mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
Study: NCT02207829
Drug: Umeclidinium
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium 62.5 mcg once daily in the morning via nDPI
Study: NCT02207829
Drug: Umeclidinium matching placebo
Normalized name: Umeclidinium
DrugBank: Clidinium (DB00771)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium matching placebo once daily in the morning via nDPI
Study: NCT02207829
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
Study: NCT02207829
Drug: Tiotropium matching placebo
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
Study: NCT03519230
Drug: Pamiparib capsule
Normalized name: Pamiparib
DrugBank: Pamiparib (DB14769)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg twice daily (BID), orally (per os-PO)
Study: NCT02778204
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg/kg oral solution as a single dose.
Study: NCT02778204
Drug: Maraviroc
Normalized name: Maraviroc
DrugBank: Maraviroc (DB04835)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg/kg oral solution given twice daily.
Study: NCT04666441
Drug: REGN10933+REGN10987 combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV or SC single dose
Study: NCT00298038
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral
Study: NCT01823393
Drug: NaCl
Normalized name: NaCl
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: valvuloplasty is performed without heparin (placebo injection)
Study: NCT00389818
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg PO Days 1-5 of each cycle
Study: NCT00389818
Drug: vincristine sulfate
Normalized name: Vincristine Sulfate
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
Study: NCT00499369
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01626976
Drug: PF-06282999
Normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution, doses range from 20 to 200 mg, single dose
Study: NCT01626976
Drug: PF-06282999
Normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose suspension, doses range 125 to 500 mg, single dose
Study: NCT01626976
Drug: PF-06282999
Normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
Study: NCT01626976
Drug: PF-06282999
Normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylcellulose or simethicone suspension, 500 mg dose, single dose
Study: NCT01626976
Drug: PF-06282999
Normalized name: PF-06282999
DrugBank: PF-06282999 (DB11683)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone or methylcellulose suspension, up to 1500 mg, single dose
Study: NCT05166005
Drug: vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomised to receive either high dose vitamin D (50,000 IU weekly) on the first and second week or low dose vitamin D (2,000 IU daily).
Study: NCT04274738
Drug: Mavorixafor
Normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavorixafor capsules will be administered per dose and schedule specified in the arm.
Study: NCT04274738
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib capsules will be administered per dose and schedule specified in the arm.
Study: NCT03952039
Drug: FEDRATINIB
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A potent and selective inhibitor of JAK2 kinase activity
Study: NCT03787849
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% for anesthesia induction. After induction and peripheral vein puncture, the anesthesia will be maintained only with sevoflurane 3% until completion of the procedure.
Study: NCT03787849
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All children will receive inhalation anesthesia with sevoflurane through facial mask in concentrations between 3-8% until lost of conscience and peripheral vein puncture. After that, sevoflurane will be turned off and its clearance will be analyzed through gas analyzer monitor. From here, anesthesia will be maintained as total venous with continuous propofol infusion 100 mcg.kg.min-1 until completion of the procedure.
Study: NCT00320281
Drug: botulinum toxin A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
Study: NCT04498897
Drug: Vortioxetine
Normalized name: Vortioxetine
DrugBank: Vortioxetine (DB09068)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate
Study: NCT04498897
Drug: Acamprosate
Normalized name: Acamprosate
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Baseline: Vortioxetine 10mg (or placebo) + Acamprosate~* First 2 weeks: Vortioxetine 5-10mg (or placebo) + Acamprosate~* Last 6 weeks: Vortioxetine 5-20mg (or placebo) + Acamprosate
Study: NCT03258476
Drug: Guanfacine Extended Release
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
Study: NCT02412267
Drug: O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
Study: NCT01055392
Drug: Lithium Carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
Study: NCT02293005
Drug: Alisertib
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg twice a day on Days 1-7 of each 21-day study cycle.
Study: NCT02642913
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02642913
Drug: Enzalutamide with Sorafenib
Normalized name: Enzalutamide
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02039531
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04011475
Drug: Tiotropium + Olodaterol
Normalized name: olodaterol / tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiolto®
Study: NCT04011475
Drug: LAMA
Normalized name: Alamag
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
Study: NCT00752505
Drug: Esreboxetine
Normalized name: Esreboxetine
DrugBank: Esreboxetine (DB12395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
Study: NCT00045994
Drug: ALT-711
Normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00147147
Drug: Gastrectomy+ chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02329405
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00126048
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg tablet
Study: NCT02192684
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 45 mg daily Insulin sensitizing
Study: NCT01607905
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants in this study will receive selinexor orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m\^2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in 4-week (28 days for schedule 1 to 7) and 3-week (21 days for schedule 8) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
Study: NCT02602288
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over the counter nicotine replacement therapy in gum or lozenge form.
Study: NCT00185133
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00185133
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01429545
Drug: Atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
Study: NCT01429545
Drug: Atosiban and nifedipine
Normalized name: atosiban
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (\<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
Study: NCT01621373
Drug: propofol administration
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
Study: NCT00000435
Drug: dnaJ peptide
Normalized name: peptide-T
DrugBank: Peptide-T (DB19279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dnaJP1 was taken in pill form at 25mg/day for 6 months
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg Capsule Once Daily (Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg Capsule Once Daily (Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg Capsule Once Daily (Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg Capsule Once Daily (Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9mg Capsule Once Daily (Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8mg Capsule Once Daily (Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4mg Capsule Twice Daily (Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg Capsule Twice Daily (Dose Escalation) Continuous
Study: NCT01105533
Drug: PF-00337210
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6mg Capsule Twice Daily (Dose Expansion) Continuous
Study: NCT01917045
Drug: Sufentanil (R30730, brand name Sufenta) + Morphine
Normalized name: sufentanil Injection [Sufenta]
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil 0.5ug/ml+morphine 0.25mg/ml
Study: NCT01917045
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine 0. 5mg/ml
Study: NCT00467181
Drug: Fenoldopam
Normalized name: Fenoldopam
DrugBank: Fenoldopam (DB00800)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02448303
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02448303
Drug: Acalabrutinib
Normalized name: Acalabrutinib
DrugBank: Acalabrutinib (DB11703)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00630877
Drug: Niacin extended-release (NER)
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
Study: NCT00630877
Drug: Niacin extended-release (NER) placebo
Normalized name: niacin Extended Release Oral Capsule
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered once daily for 6 weeks
Study: NCT00630877
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets (325 mg) administered once daily for 6 weeks
Study: NCT00630877
Drug: Aspirin (ASA) placebo
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets administered once daily for 6 weeks
Study: NCT04599881
Drug: PTR-01
Normalized name: PTR-01
DrugBank: PTR-01 (DB17900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV recombinant collagen 7 at 3 mg/kg given weekly for 4 doses, followed by bi-weekly for 7 doses
Study: NCT01428492
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
Study: NCT01428492
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
Study: NCT00030589
Drug: bexarotene
Normalized name: Bexarotene
DrugBank: Bexarotene (DB00307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00030589
Drug: methoxsalen
Normalized name: Methoxsalen
DrugBank: Methoxsalen (DB00553)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04313153
Drug: Vadadustat
Normalized name: vadadustat
DrugBank: Vadadustat (DB12255)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: oral tablets
Study: NCT04313153
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravenous or subcutaneous solution
Study: NCT02033889
Drug: Ertugliflozin 5 mg
Normalized name: ertugliflozin 5 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
Study: NCT02033889
Drug: Ertugliflozin 15 mg
Normalized name: ertugliflozin 15 MG
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
Study: NCT02033889
Drug: Placebo to Ertugliflozin
DrugBank: Ertugliflozin (DB11827)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
Study: NCT02033889
Drug: Placebo to Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
Study: NCT02033889
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin \>=1500 mg/day, orally, once a day
Study: NCT03757559
Drug: Cebranopadol 100 micrograms
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets were taken under fasted conditions with non-carbonated water.
Study: NCT03757559
Drug: Cebranopadol 400 micrograms
Normalized name: Cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets were taken under fasted conditions with non-carbonated water.
Study: NCT03757559
Drug: Hydromorphone hydrochloride 4 milligrams
Normalized name: hydromorphone hydrochloride 4 MG
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Over-encapsulated immediate-release tablets were taken under fasted conditions with non-carbonated water.
Study: NCT03757559
Drug: Placebo matching hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo matching over-encapsulated hydromorphone tablets were taken under fasted conditions with non-carbonated water.
Study: NCT03757559
Drug: Placebo matching cebranopadol
DrugBank: Cebranopadol (DB12830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching cebranopadol tablets were taken under fasted conditions with non-carbonated water.
Study: NCT04255862
Drug: Bimekizumab
Normalized name: bimekizumab
DrugBank: Bimekizumab (DB12917)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Study participants will receive a single-dose of bimekizumab administered subcutaneously in the Treatment Period.
Study: NCT03773744
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: monoclonal antibody; checkpoint inhibitor of PD1
Study: NCT04286035
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Femoral nerve block with 20 ml %0.375 bupivacaine
Study: NCT04286035
Drug: Bupivacaine Injection
Normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adductor canal block with 20 ml %0.375 bupivacaine
Study: NCT02873923
Drug: undefined
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy drug (meta-analyses of randomized trials)
Study: NCT02193620
Drug: PHN131 soft capsule with Nalbuphine HCl 60 mg/cap
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
Study: NCT03737214
Drug: Lucerastat
Normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered in hard gelatin capsules containing 250 mg of lucerastat.
Study: NCT04175262
Drug: sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients to receive sunitinib as second line therapy for mRCC
Study: NCT01969838
Drug: Momelotinib
Normalized name: MOMELOTINIB
DrugBank: Momelotinib (DB11763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Momelotinib tablet administered orally once daily
Study: NCT01969838
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib tablets administered orally twice daily